Global biopharmaceutical company UCB (Euronext Brussels:UCB) and US biotechnology company Biogen Inc (NASDAQ:BIIB) on Monday announced additional clinical findings for dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2026 meeting.

A post-hoc analysis of the Phase 3 PHOENYCS GO trial found that patients receiving DZP plus standard of care (SOC) achieved higher treatment response rates than those receiving placebo plus SOC, based on the novel Treatment Response Measure for SLE (TRM-SLE). At Week 48, response rates were 61.2% versus 43.2% for improvement across at least half of active organ domains, mainly joints and skin, and 52.5% versus 36.8% for improvement across all active domains.

Separate analyses also demonstrated higher rates of sustained low disease activity and remission with DZP plus SOC across Weeks 40, 44 and 48, compared with placebo plus SOC.

In the PHOENYCS GO trial DZP plus SOC met its primary endpoint, achieving a 50% BICLA response rate at Week 48, compared with 35% for placebo plus SOC.

The additional findings are being presented across five posters at ACR Convergence 2026 in Orlando, Florida, from November 6 to 11.